TH006 reduced tau levels and improved viability in Aβ-treated primary neuron cells and in 3xTg-AD mice, which harbor three mutations associated with familial AD and exhibit both tau and Aβ pathology. This evidence concerns the gene MAPT and Alzheimer disease.